179 related articles for article (PubMed ID: 37965778)
1. The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.
Wang Y; Xu J; Lan T; Zhou C; Liu P
Cancer Med; 2023 Dec; 12(24):21651-21665. PubMed ID: 37965778
[TBL] [Abstract][Full Text] [Related]
2. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.
Francisco-Cruz A; Rocha P; Reuben A; Krishnan SN; Das P; Chen R; Quek K; Li J; Parra ER; Solis LM; Barua S; Jiang M; Lazcano R; Chow CW; Behrens C; Gumb C; Little L; Fukuoka J; Kalhor N; Weissferdt A; Kadara H; Heymach JV; Swisher S; Sepesi B; Rao A; Moran C; Zhang J; Lee JJ; Fujimoto J; Futreal PA; Wistuba II; Peterson CB; Zhang J
Mod Pathol; 2023 Jan; 36(1):100028. PubMed ID: 36788067
[TBL] [Abstract][Full Text] [Related]
4. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
Reuben A; Gittelman R; Gao J; Zhang J; Yusko EC; Wu CJ; Emerson R; Zhang J; Tipton C; Li J; Quek K; Gopalakrishnan V; Chen R; Vence LM; Cascone T; Vignali M; Fujimoto J; Rodriguez-Canales J; Parra ER; Little LD; Gumbs C; Forget MA; Federico L; Haymaker C; Behrens C; Benzeno S; Bernatchez C; Sepesi B; Gibbons DL; Wargo JA; William WN; Swisher S; Heymach JV; Robins H; Lee JJ; Sharma P; Allison JP; Futreal PA; Wistuba II; Zhang J
Cancer Discov; 2017 Oct; 7(10):1088-1097. PubMed ID: 28733428
[TBL] [Abstract][Full Text] [Related]
5. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
6. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.
Yang H; Yu M; Zhong S; You Y; Feng F
J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
8. Intratumor heterogeneity is associated with less CD8
Zhang C; Li Z; Shang X; Zhao C; Wang H
Clin Transl Oncol; 2023 Apr; 25(4):1043-1052. PubMed ID: 36422799
[TBL] [Abstract][Full Text] [Related]
9. DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy.
Li L; Chen C; Wang X
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34096997
[TBL] [Abstract][Full Text] [Related]
10. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
11. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
12. The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.
Anzar I; Malone B; Samarakoon P; Vardaxis I; Simovski B; Fontenelle H; Meza-Zepeda LA; Stratford R; Keung EZ; Burgess M; Tawbi HA; Myklebost O; Clancy T
Front Immunol; 2023; 14():1226445. PubMed ID: 37799721
[TBL] [Abstract][Full Text] [Related]
13. Genomic pattern of intratumor heterogeneity predicts the risk of progression in early stage diffuse large B-cell lymphoma.
Wang Y; Feng W; Liu P
Carcinogenesis; 2019 Nov; 40(11):1427-1434. PubMed ID: 31220210
[TBL] [Abstract][Full Text] [Related]
14. Tumor Neoantigens: When Too Much of a Good Thing Is Bad.
Trinh A; Polyak K
Cancer Cell; 2019 Nov; 36(5):466-467. PubMed ID: 31715129
[TBL] [Abstract][Full Text] [Related]
15. NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline.
Schenck RO; Lakatos E; Gatenbee C; Graham TA; Anderson ARA
BMC Bioinformatics; 2019 May; 20(1):264. PubMed ID: 31117948
[TBL] [Abstract][Full Text] [Related]
16. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
Elife; 2023 Aug; 12():. PubMed ID: 37548358
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen landscape in metastatic nasopharyngeal carcinoma.
Lin M; Zhang XL; You R; Yang Q; Zou X; Yu K; Liu YP; Zou RH; Hua YJ; Huang PY; Wang J; Zhao Q; Jiang XB; Tang J; Gu YK; Yu T; He GP; Xie YL; Wang ZQ; Liu T; Chen SY; Zuo ZX; Chen MY
Theranostics; 2021; 11(13):6427-6444. PubMed ID: 33995666
[No Abstract] [Full Text] [Related]
18. Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.
Huang J; Zhao G; Peng Q; Yi X; Ji L; Li J; Li P; Guan Y; Ge J; Chen L; Chen R; Hu X; Lee WC; Reuben A; Futreal PA; Xia X; Ma J; Zhang J; Chen Z
Mol Oncol; 2023 Aug; 17(8):1531-1544. PubMed ID: 36703611
[TBL] [Abstract][Full Text] [Related]
19. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK
Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974
[TBL] [Abstract][Full Text] [Related]
20. A novel integrated approach to predicting cancer immunotherapy efficacy.
Luo R; Chyr J; Wen J; Wang Y; Zhao W; Zhou X
Oncogene; 2023 Jun; 42(23):1913-1925. PubMed ID: 37100920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
